Omeros Corporation (NASDAQ:OMER) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Analysts rate Omeros “Moderate Buy.” Among six analysts, three recommend holding, two recommend buying, and one gives a strong-buy rating; the average 12-month price target is $38.00.
• Omeros shares opened at $19.12, near their 52-week high of $19.65, while the company reported quarterly earnings of $0.02 per share—beating the consensus estimate of a $0.27 loss—and revenue of $28.53 million.
• Insiders have been selling shares: executives sold 95,906 shares worth approximately $1.78 million over the past 90 days. Institutional investors and hedge funds own 48.79% of the company.

Omeros Corporation (NASDAQ:OMER - Get Free Report) has received an average recommendation of "Moderate Buy" from the six research firms that are currently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $38.00.

Several research analysts have commented on OMER shares. HC Wainwright reaffirmed a "buy" rating on shares of Omeros in a research report on Monday, July 27th. Zacks Research lowered shares of Omeros from a "strong-buy" rating to a "hold" rating in a research report on Monday, July 13th. Weiss Ratings raised shares of Omeros from a "hold (c-)" rating to a "hold (c)" rating in a report on Thursday, September 3rd. Finally, Wall Street Zen upgraded shares of Omeros from a "hold" rating to a "buy" rating in a report on Saturday, August 15th.

Omeros Trading Up 0.9%

NASDAQ:OMER opened at $19.12 on Wednesday. Omeros has a 1 year low of $3.94 and a 1 year high of $19.65. The firm's fifty day simple moving average is $13.89 and its 200 day simple moving average is $12.39. The firm has a market capitalization of $1.38 billion, a PE ratio of 14.94 and a beta of 2.60.

Omeros (NASDAQ:OMER - Get Free Report) last released its earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.29. The firm had revenue of $28.53 million for the quarter, compared to analyst estimates of $12.69 million. As a group, analysts anticipate that Omeros will post -0.37 EPS for the current fiscal year.

Insider Buying and Selling at Omeros

In other news, CAO David Borges sold 10,000 shares of the firm's stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $18.95, for a total transaction of $189,500.00. Following the completion of the transaction, the chief accounting officer directly owned 5,906 shares of the company's stock, valued at approximately $111,918.70. This trade represents a 62.87% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Peter B. Cancelmo sold 25,000 shares of the company's stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $18.54, for a total transaction of $463,500.00. Following the completion of the sale, the vice president directly owned 200 shares in the company, valued at approximately $3,708. The trade was a 99.21% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 95,906 shares of company stock worth $1,780,205. Corporate insiders own 10.50% of the company's stock.

Institutional Trading of Omeros

Several institutional investors have recently bought and sold shares of OMER. State of Wyoming acquired a new stake in shares of Omeros in the 4th quarter valued at $25,000. Caitong International Asset Management Co. Ltd bought a new stake in Omeros during the fourth quarter worth about $33,000. Assetmark Inc. bought a new stake in Omeros during the first quarter worth about $38,000. Arax Advisory Partners increased its holdings in shares of Omeros by 56.4% during the fourth quarter. Arax Advisory Partners now owns 5,255 shares of the biopharmaceutical company's stock worth $90,000 after buying an additional 1,894 shares in the last quarter. Finally, International Assets Investment Management LLC increased its holdings in shares of Omeros by 16.0% during the first quarter. International Assets Investment Management LLC now owns 5,800 shares of the biopharmaceutical company's stock worth $61,000 after buying an additional 800 shares in the last quarter. Institutional investors and hedge funds own 48.79% of the company's stock.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company's research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros's portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros's first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.